GlassScriptPhysician profile
Anita Nahar
NPI 1659369684
$6,884.91
in general payments reported to CMS, 2019-2025
31 companies · $1,401 in 2025
The $1,401 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $392 · 2021: $741 · 2022: $1,174 · 2023: $1,141 · 2024: $1,551 · 2025: $1,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,038 · Education: $55.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,037.99 |
| Education | $55.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $998.79 | 2020-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $731.08 | 2021-2025 | |
| Vifor Pharma, INC. | $633.87 | 2019-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $567.56 | 2019-2025 | Jynarque |
| Ani Pharmaceuticals, INC. | $527.31 | 2022-2025 | Purified Cortrophin Gel |
| Amgen INC. | $403.42 | 2021-2025 | Tavneos, Krystexxa, Aranesp |
| Calliditas Therapeutics US INC. | $368.12 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $325.28 | 2021-2024 | Lupkynis |
| Travere Therapeutics, INC. | $313.97 | 2022-2025 | Filspari |
| Horizon Therapeutics Plc | $286.09 | 2019-2023 | Krystexxa, Tepezza |
| Astrazeneca Pharmaceuticals LP | $209.04 | 2019-2023 | Farxiga |
| Fresenius USA Marketing, INC. | $203.87 | 2019-2025 | Velphoro, Velphoro |
| Novo Nordisk INC | $179.54 | 2024-2025 | Ozempic, Rivfloza, Wegovy |
| Alexion Pharmaceuticals, INC. | $143.83 | 2020-2024 | Ultomiris |
| Daiichi Sankyo INC. | $143.37 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $137.60 | 2019-2025 | Vafseo, Auryxia |
| Ardelyx, INC. | $97.34 | 2023-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $86.81 | 2023-2024 | Jesduvroq, Benlysta |
| Scpharmaceuticals INC. | $81.14 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $69.10 | 2025 | |
| Alnylam Pharmaceuticals INC. | $62.17 | 2021-2025 | Amvuttra, Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.06 | 2023-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $50.33 | 2022 | |
| Genentech USA, INC. | $43.42 | 2025 | Gazyva |
| Amag Pharmaceuticals, INC. | $31.12 | 2020-2021 | |
| Kyowa Kirin, INC. | $25.98 | 2025 | |
| Boston Scientific Corporation | $24.85 | 2022 | |
| Apellis Pharmaceuticals, INC. | $23.35 | 2025 | Empaveli |
| Mallinckrodt Enterprises LLC | $23.01 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.84 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.65 | 2024 | Jynarque |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anita Nahar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.